Delving into the Latest Updates on NeuroGate Therapeutics, Inc. with Synapse

概览

关联

1

项与 NeuroGate Therapeutics, Inc. 相关的药物

NGT-110

靶点

Nav1.7

作用机制

Nav1.7调节剂

在研机构-

原研机构

NeuroGate Therapeutics, Inc.

在研适应症-

非在研适应症

癫痫 [+1]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

100 项与 NeuroGate Therapeutics, Inc. 相关的临床结果

登录后查看更多信息

0 项与 NeuroGate Therapeutics, Inc. 相关的专利（医药）

登录后查看更多信息

2

项与 NeuroGate Therapeutics, Inc. 相关的文献（医药）

2015-07-01·Bioorganic & Medicinal Chemistry3区 · 医学

Chimeric derivatives of functionalized amino acids and α-aminoamides: Compounds with anticonvulsant activity in seizure models and inhibitory actions on central, peripheral, and cardiac isoforms of voltage-gated sodium channels

3区 · 医学

Article

作者: Torregrosa, Robert ; Khanna, Rajesh ; Kohn, Harold ; Yang, Xiao-Fang ; Cummins, Theodore R ; Dustrude, Erik T

Six novel 3″-substituted (R)-N-(phenoxybenzyl) 2-N-acetamido-3-methoxypropionamides were prepared and then assessed using whole-cell, patch-clamp electrophysiology for their anticonvulsant activities in animal seizure models and for their sodium channel activities. We found compounds with various substituents at the terminal aromatic ring that had excellent anticonvulsant activity. Of these compounds, (R)-N-4'-((3″-chloro)phenoxy)benzyl 2-N-acetamido-3-methoxypropionamide ((R)-5) and (R)-N-4'-((3″-trifluoromethoxy)phenoxy)benzyl 2-N-acetamido-3-methoxypropionamide ((R)-9) exhibited high protective indices (PI=TD50/ED50) comparable with many antiseizure drugs when tested in the maximal electroshock seizure test to mice (intraperitoneally) and rats (intraperitoneally, orally). Most compounds potently transitioned sodium channels to the slow-inactivated state when evaluated in rat embryonic cortical neurons. Treating HEK293 recombinant cells that expressed hNaV1.1, rNaV1.3, hNaV1.5, or hNaV1.7 with (R)-9 recapitulated the high levels of sodium channel slow inactivation.

PMC

Chimeric derivatives of functionalized amino acids and α-aminoamides: compounds with anticonvulsant activity in seizure models and inhibitory actions on central, peripheral, and cardiac isoforms of voltage-gated sodium channels

作者: Xiao-Fang Yang ; Theodore R. Cummins ; Erik T. Dustrude ; Harold Kohn ; Robert Torregrosa ; Rajesh Khanna

Abstract Six novel 3″-substituted (R)-N-(phenoxybenzyl) 2-N-acetamido-3-methoxypropionamides were prepared and then assessed using whole-cell, patch-clamp electrophysiology for their anticonvulsant activities in animal seizure models and for their sodium channel activities. We found compounds with various substituents at the terminal aromatic ring that had excellent anticonvulsant activity. Of these compounds, (R)-N-4′-((3″-chloro)phenoxy)benzyl 2-N-acetamido-3-methoxypropionamide ((R)-5) and (R)-N-4′-((3″-trifluoromethoxy)phenoxy)benzyl 2-N-acetamido-3-methoxypropionamide ((R)-9) exhibited high protective indices (PI = TD50/ED50) comparable with many antiseizure drugs when tested in the maximal electroshock seizure test to mice (intraperitoneally) and rats (intraperitoneally, orally). Most compounds potently transitioned sodium channels to the slow-inactivated state when evaluated in rat embryonic cortical neurons. Treating HEK293 recombinant cells that expressed hNaV1.1, rNaV1.3, hNaV1.5, or hNaV1.7 with (R)-9 recapitulated the high levels of sodium channel slow inactivation.

100 项与 NeuroGate Therapeutics, Inc. 相关的药物交易

登录后查看更多信息

100 项与 NeuroGate Therapeutics, Inc. 相关的转化医学

登录后查看更多信息